Income Statement China Isotope & Radiation Corporation
Stocks
1763
CNE1000031F4
Medical Equipment, Supplies & Distribution
|
Market Closed -
Hong Kong S.E.
04:08:33 2026-08-28 EDT
|
5-day change | 1st Jan Change | ||
| 17.00 HKD | -0.12% |
|
+2.04% | -15.84% |
| 07-05 | China Isotope to Form JV With Associate | MT |
| 07-03 | China Isotope & Radiation Corporation and CNNC Yuanke Enter into Shareholders? Agreement to Establish Joint Venture Company CNNC Fuyuan | CI |
| Fiscal Period: December | 2016 (CNY) | 2017 (CNY) | 2018 (CNY) | 2019 (CNY) | 2020 (CNY) | 2021 (CNY) | 2022 (CNY) | 2023 (CNY) | 2024 (CNY) | 2025 (CNY) |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 5.14B | 6.15B | 6.63B | 7.57B | 7.19B | |||||
Total Revenues | 5.14B | 6.15B | 6.63B | 7.57B | 7.19B | |||||
Cost of Goods Sold, Total | 1.9B | 2.63B | 3.15B | 3.89B | 3.57B | |||||
Gross Profit | 3.24B | 3.51B | 3.48B | 3.68B | 3.62B | |||||
Selling General & Admin Expenses, Total | 2.32B | 2.36B | 2.41B | 2.33B | 2.33B | |||||
Provision for Bad Debts | 11M | 31.19M | 71.24M | 45.54M | 44.47M | |||||
R&D Expenses | 196M | 301M | 306M | 300M | 302M | |||||
Other Operating Expenses | -28.36M | -53.77M | -50.32M | -72.24M | -74.25M | |||||
Other Operating Expenses, Total | 2.5B | 2.64B | 2.73B | 2.6B | 2.6B | |||||
Operating Income | 743M | 874M | 750M | 1.08B | 1.02B | |||||
Interest Expense, Total | -34.04M | -32.72M | -34.83M | -47.2M | -64.05M | |||||
Interest And Investment Income | 30.99M | 51.69M | 36.57M | 34.09M | 37.38M | |||||
Net Interest Expenses | -3.05M | 18.97M | 1.74M | -13.12M | -26.67M | |||||
Income (Loss) On Equity Invest. | 60.66M | 42.17M | 16.98M | 7.26M | 16.55M | |||||
Currency Exchange Gains (Loss) | -1.65M | -13.29M | -4.39M | -9.44M | -7.82M | |||||
Other Non Operating Income (Expenses) | - | - | - | - | -5.83M | |||||
EBT, Excl. Unusual Items | 799M | 922M | 764M | 1.06B | 996M | |||||
Gain (Loss) On Sale Of Investments | 4.55M | - | - | -19.34M | -796K | |||||
Gain (Loss) On Sale Of Assets | -683K | -1.12M | 158M | -197K | 9.56M | |||||
Asset Writedown | - | - | - | - | -224K | |||||
Other Unusual Items | - | 125K | - | 160K | 80K | |||||
EBT, Incl. Unusual Items | 803M | 921M | 922M | 1.05B | 1B | |||||
Income Tax Expense | 130M | 166M | 146M | 166M | 340M | |||||
Earnings From Continuing Operations | 673M | 755M | 776M | 880M | 665M | |||||
Net Income to Company | 673M | 755M | 776M | 880M | 665M | |||||
Minority Interest | -337M | -363M | -405M | -473M | -337M | |||||
Net Income - (IS) | 336M | 392M | 371M | 407M | 327M | |||||
Net Income to Common Incl Extra Items | 336M | 392M | 371M | 407M | 327M | |||||
Net Income to Common Excl. Extra Items | 336M | 392M | 371M | 407M | 327M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 1.05 | 1.22 | 1.16 | 1.27 | 1.02 | |||||
Basic EPS - Continuing Operations | 1.05 | 1.22 | 1.16 | 1.27 | 1.02 | |||||
Basic Weighted Average Shares Outstanding | 320M | 320M | 320M | 320M | 320M | |||||
Net EPS - Diluted | 1.05 | 1.22 | 1.16 | 1.27 | 1.02 | |||||
Diluted EPS - Continuing Operations | 1.05 | 1.22 | 1.16 | 1.27 | 1.02 | |||||
Diluted Weighted Average Shares Outstanding | 320M | 320M | 320M | 320M | 320M | |||||
Normalized Basic EPS | 0.51 | 0.67 | 0.23 | 0.6 | 0.89 | |||||
Normalized Diluted EPS | 0.51 | 0.67 | 0.23 | 0.6 | 0.89 | |||||
Dividend Per Share | 0.38 | 0.44 | 0.31 | 0.38 | 0.31 | |||||
Payout Ratio | 17.18 | 30.87 | 38 | 30.32 | 38.07 | |||||
Supplemental Items | ||||||||||
EBITDA | 901M | 1.05B | 973M | 1.29B | 1.24B | |||||
EBITA | 754M | 882M | 762M | 1.09B | 1.03B | |||||
EBIT | 743M | 874M | 750M | 1.08B | 1.02B | |||||
EBITDAR | 904M | 1.06B | - | - | - | |||||
Effective Tax Rate - (Ratio) | 16.15 | 18.03 | 15.86 | 15.85 | 33.82 | |||||
Current Domestic Taxes | 144M | 174M | - | 232M | 400M | |||||
Total Current Taxes | 144M | 174M | 167M | 232M | 400M | |||||
Deferred Domestic Taxes | -14.08M | -7.88M | - | -66.68M | -60.01M | |||||
Total Deferred Taxes | -14.08M | -7.88M | -20.52M | -66.68M | -60.01M | |||||
Normalized Net Income | 162M | 213M | 72.35M | 192M | 285M | |||||
Interest Capitalized | 5.13M | 5.33M | 9.61M | 16.43M | 16.43M | |||||
Interest on Long-Term Debt | 26.8M | 26.09M | 3.23M | 5.22M | 15M | |||||
Non-Cash Pension Expense | 1.76M | 1.68M | 1.32M | 1.22M | 1.14M | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | - | - | - | - | - | |||||
Marketing Expenses | - | - | - | - | - | |||||
Selling and Marketing Expenses | 1.82B | 1.79B | 1.77B | 1.62B | 1.45B | |||||
General and Administrative Expenses | 498M | 573M | 636M | 705M | 880M | |||||
Research And Development Expense From Footnotes | 196M | 301M | 306M | 300M | 302M | |||||
Net Rental Expense, Total | 2.91M | 9.03M | - | - | - | |||||
Imputed Operating Lease Interest Expense | 1.14M | 3.16M | - | - | - | |||||
Imputed Operating Lease Depreciation | 1.78M | 5.87M | - | - | - | |||||
Maintenance & Repair Expenses, Total | - | - | - | - | - | |||||
Stock-Based Comp., Other (Total) | - | - | - | - | - | |||||
Total Stock-Based Compensation | - | - | - | - | - |
Select your edition
All financial news and data tailored to specific country editions
















